Trials / Completed
CompletedNCT00688415
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VTX-2337 | Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified. |
Timeline
- Start date
- 2008-11-07
- Primary completion
- 2010-08-01
- Completion
- 2010-11-01
- First posted
- 2008-06-03
- Last updated
- 2019-09-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00688415. Inclusion in this directory is not an endorsement.